| Literature DB >> 32513240 |
Barbara Clyne1, Fiona Boland2, Norah Murphy2, Edel Murphy3, Frank Moriarty2, Alan Barry2, Emma Wallace2, Tatyana Devine2, Susan M Smith2, Declan Devane4, Andrew Murphy5, Tom Fahey2.
Abstract
BACKGROUND: Despite efforts to improve the accuracy and transparency of the design, conduct, and reporting of randomised controlled trials (RCTs), deficiencies remain. Such deficiencies contribute to significant, avoidable waste of health research investment and impede reproducibility. This study aimed to synthesise and critically analyse changes over time in the conduct and reporting of internationally published evidence on patient and/or population health-oriented RCTs conducted in one country.Entities:
Mesh:
Year: 2020 PMID: 32513240 PMCID: PMC7278139 DOI: 10.1186/s13063-020-04396-x
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Flow diagram of studies screened
Fig. 2Number of studies published and proportion meeting reporting standards per year
Study characteristics
| Characteristic | n (752) | % |
|---|---|---|
| Parallel | 643 | 85.5 |
| Crossover | 76 | 10.1 |
| Cluster | 23 | 3.1 |
| Other | 10 | 1.3 |
| Hospital (inpatient) | 314 | 41.8 |
| Ambulatory (outpatient) | 276 | 36.7 |
| Primary care | 70 | 9.3 |
| Other | 92 | 12.2 |
| Adults | 549 | 73.0 |
| Pregnant women | 47 | 6.3 |
| Older people (≥ 65 years) | 46 | 6.1 |
| Children (≤ 18 years) | 43 | 5.7 |
| Infants (author defined) | 16 | 2.1 |
| Other | 41 | 5.5 |
| Not stated | 10 | 1.3 |
| Alternative intervention | 298 | 39.6 |
| Usual care | 270 | 35.9 |
| Placebo | 160 | 21.3 |
| Other | 24 | 3.2 |
| Not stated | 412 | 54.8 |
| Government body/agency | 103 | 13.7 |
| Industry | 89 | 11.8 |
| Multiple funders | 47 | 6.3 |
| Charity | 40 | 5.3 |
| University | 14 | 1.9 |
| No funding | 3 | 0.4 |
| Other | 44 | 5.9 |
a All categories are mutually exclusive
Health Research Classification System (HRCS) category research activity
| HRCS category | n (752) | % |
|---|---|---|
| 2.1 Biological and endogenous factors | 1 | 0.13 |
| 2.3 Psychological, social and economic factors | 1 | 0.13 |
| 3.2 Interventions to alter physical and biological environmental risks | 5 | 0.66 |
| 3.3 Nutrition and chemoprevention | 1 | 0.13 |
| 4.2 Evaluation of markers and technologies | 10 | 1.33 |
| 4.4 Population screening | 2 | 0.27 |
| 6.1 Pharmaceuticals | 356 | 47.34 |
| 6.3 Medical devices | 71 | 9.44 |
| 6.4 Surgery | 69 | 9.18 |
| 6.5 Radiotherapy and other non-invasive therapies | 21 | 2.79 |
| 6.6 Psychological and behavioural | 75 | 9.97 |
| 6.7 Physical | 88 | 11.70 |
| 6.8 Complementary | 3 | 0.40 |
| 6.9 Resources and infrastructure (treatment evaluation) | 18 | 2.39 |
| 8.1 Organisation and delivery of services | 31 | 4.12 |
Top five diseases or conditions and procedures
| Diseases of the circulatory system | 52 | 13 |
| Mental and behavioural disorders | 47 | 11.7 |
| Diseases of nervous system | 40 | 10 |
| Diseases of the digestive system | 37 | 9.2 |
| Diseases of the musculoskeletal system | 22 | 5.5 |
| Non-invasive, cognitive and other interventions, not elsewhere classified | 115 | 45.5 |
| Obstetric procedures | 29 | 12.5 |
| Procedures on musculoskeletal system | 21 | 8.3 |
| Procedures on digestive system | 16 | 6.3 |
| Procedures on cardiovascular system | 15 | 5.9 |
Fig. 3Risk of bias graph